Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 1,825-1,836 of 4,306
Drug study icon
Not recruitingEUCTR 2021-003714-39

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

Multiple locations, including Kazanlak
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.
Countries
Bulgaria, Croatia, Czechia, ...
Sponsor
Neurocrine Biosciences, Inc.
Condition
Schizophrenia
Drug study icon
Not recruitingEUCTR 2022-001665-12

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

Multiple locations, including Cherven Bryag
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria
Sponsor
Karuna Therapeutics, Inc.
Condition
Schizophrenia
Drug study icon
Not recruitingEUCTR 2006-006967-22

A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Estonia
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France, United Kingdom, Estonia, ...
Sponsor
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Condition
Schizophrenia
Other study type icon
Not recruitingISRCTN56473864

A controlled study of short-term intensive community case management of severe mental illness: an assessment of its benefit to 'heavy users' of hospital services and cost effectiveness

This study is not recruiting in the United Kingdom. It focuses on Schizophrenia.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

Schizophrenia, Depression, ...Other
Countries
United Kingdom
Sponsor
NHS R&D Regional Programme Register - Department of Health (UK)
Condition
Schizophrenia, Depression, ...
Drug study icon
Not recruitingEUCTR 2011-004889-15

A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Belgium, Austria, Bulgaria, ...
Sponsor
Janssen-Cilag International N.V.
Condition
Schizophrenia
Drug study icon
Not recruitingISRCTN81682255

Adherence therapy for people with schizophrenia in Suanprung Psychiatric Hospital, Thailand

This study is testing a medication approach for people with Schizophrenia or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaOther
Countries
United Kingdom, Thailand
Sponsor
Praboromarajanok Institute of Workforce Development (Thailand)
Condition
Schizophrenia
Drug study icon
Not recruitingEUCTR 2022-001666-35

An Open Label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

Multiple locations, including Cherven Bryag
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria
Sponsor
Karuna Therapeutics, Inc.
Condition
Schizophrenia
Drug study icon
Not recruitingEUCTR 2019-000696-16

An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria, Croatia, Latvia
Sponsor
Sunovion Pharmaceuticals Inc.
Condition
Schizophrenia
Behavioral study icon
Not recruitingISRCTN75187865

Cognitive remediation for young people with schizophrenia

This study is looking at whether Cognitive remediation therapy versus usual care can help people with Schizophrenia or Mental and Behavioural Disorders. Participants take part in Cognitive remediation therapy versus usual care and complete follow-up assessments.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaOther
Countries
United Kingdom
Sponsor
King's College London (UK)
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.